Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, Odunsi K, Creighton CJ, Lev DC, Anderson ML.

Clin Cancer Res. 2012 Jun 15;18(12):3352-65. doi: 10.1158/1078-0432.CCR-11-3058. Epub 2012 Apr 25.

2.

Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, Zhang Y, Huang KL, Lazar AJ, Hunt KK, Pollock RE, Creighton CJ, Anderson ML, Lev D.

Clin Cancer Res. 2012 Sep 1;18(17):4633-45. doi: 10.1158/1078-0432.CCR-12-0436. Epub 2012 Jul 20.

3.

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y.

Mol Cancer Ther. 2010 Jan;9(1):157-66. doi: 10.1158/1535-7163.MCT-09-0609. Epub 2010 Jan 6.

4.

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE.

Clin Cancer Res. 2013 Apr 1;19(7):1717-28. doi: 10.1158/1078-0432.CCR-12-2383. Epub 2013 Feb 12.

5.

Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Yuan J, Sanhaji M, Krämer A, Reindl W, Hofmann M, Kreis NN, Zimmer B, Berg T, Strebhardt K.

Am J Pathol. 2011 Oct;179(4):2091-9. doi: 10.1016/j.ajpath.2011.06.031. Epub 2011 Aug 10.

6.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK.

Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922.

7.

Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.

Li J, Hong MJ, Chow JP, Man WY, Mak JP, Ma HT, Poon RY.

Oncotarget. 2015 Apr 20;6(11):9327-40.

8.

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.

Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM.

Cell Cycle. 2014;13(14):2237-47. doi: 10.4161/cc.29267. Epub 2014 May 29.

9.

Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.

Chinn DC, Holland WS, Mack PC.

J Cancer Res Clin Oncol. 2014 Jul;140(7):1137-49. doi: 10.1007/s00432-014-1675-6. Epub 2014 Apr 23.

10.

Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.

Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H.

J Clin Oncol. 2015 Apr 1;33(10):1180-5. doi: 10.1200/JCO.2014.58.3781. Epub 2015 Feb 23.

11.

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN.

Breast Cancer Res Treat. 2012 Sep;135(2):433-44. doi: 10.1007/s10549-012-2171-9. Epub 2012 Jul 24.

PMID:
22825030
12.

Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W.

Clin Cancer Res. 2012 Apr 15;18(8):2210-9. doi: 10.1158/1078-0432.CCR-11-2413. Epub 2012 Feb 28. Erratum in: Clin Cancer Res. 2015 Nov 15;21(22):5181.

13.

Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.

Eskander RN, Randall LM, Sakai T, Guo Y, Hoang B, Zi X.

J Obstet Gynaecol Res. 2012 Aug;38(8):1086-94. doi: 10.1111/j.1447-0756.2011.01841.x. Epub 2012 Apr 30.

14.

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.

Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D.

Int J Cancer. 2012 Jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. Epub 2011 Nov 19.

15.

A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.

Chowdhury A, Chowdhury S, Tsai MY.

Leuk Lymphoma. 2012 Mar;53(3):462-71. doi: 10.3109/10428194.2011.619018. Epub 2011 Oct 24.

PMID:
21879811
16.

A MEK-independent role for CRAF in mitosis and tumor progression.

Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA.

Nat Med. 2011 Nov 13;17(12):1641-5. doi: 10.1038/nm.2464.

17.

6,7-Dimethoxy-3-(3-methoxyphenyl)isoquinolin-1-amine induces mitotic arrest and apoptotic cell death through the activation of spindle assembly checkpoint in human cervical cancer cells.

Chung KS, Choi HE, Shin JS, Cho YW, Choi JH, Cho WJ, Lee KT.

Carcinogenesis. 2013 Aug;34(8):1852-60. doi: 10.1093/carcin/bgt133. Epub 2013 Apr 24.

PMID:
23615402
18.

PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.

Inoue M, Yoshimura M, Kobayashi M, Morinibu A, Itasaka S, Hiraoka M, Harada H.

Sci Rep. 2015 Oct 27;5:15666. doi: 10.1038/srep15666.

19.

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP, Mahadevan D.

Biochem Pharmacol. 2011 Apr 1;81(7):881-90. doi: 10.1016/j.bcp.2011.01.017. Epub 2011 Feb 1.

20.

Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.

Shionome Y, Yan L, Liu S, Saeki T, Ouchi T.

PLoS One. 2013;8(1):e55457. doi: 10.1371/journal.pone.0055457. Epub 2013 Jan 31.

Supplemental Content

Support Center